APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells

Pancreatic cancer (PC) is a disease with a high mortality rate, and the early diagnosis of PC is still challenging. The 5-year relative survival rate remains below 8%, and therapeutic strategies are ineffective at increasing patient survival rates. In PC cells, resistance to treatment has been asso...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ali Haider Alhammer, Shaymaa Ismael Al-juboori, Shahad Ali Mudhafar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	University of Baghdad, College of Science for Women 2024-08-01
Edice:	مجلة بغداد للعلوم
Témata:	APR-246, Combination, Doxorubicin, Pancreatic Cancer, p53 reactivator
On-line přístup:	https://bsj.uobaghdad.edu.iq/index.php/BSJ/article/view/10135
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!